BioCentury
ARTICLE | Clinical News

Verastem reports Phase II data for defactinib in MPM

May 26, 2017 5:21 PM UTC

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago next month, Verastem Inc. (NASDAQ:VSTM) reported data from a Phase II trial in 30 patients with malignant pleural mesothelioma (MPM) showing that twice-daily 400 mg defactinib led to 4 partial responses and 20 cases of stable disease. The open-label, U.S. trial enrolled patients with MPM prior to planned surgical resection to receive twice-daily 400 mg defactinib for 12, 21 or 35 days.

The trial is evaluating a primary endpoint of biomarker response. Secondary endpoints include safety, pharmacokinetics and tumor response...